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SIGNIFICANCE
Psoriasis is characterized by hyperproliferative keratinocytes 
and immune cell infiltration. Histamine has pro-inflammatory 
properties; it stimulates the proliferation of keratinocytes, 
and the histamine concentration in skin is increased in pso-
riatic lesions. However, classical antihistamines (histamine 
1 receptor antagonists) play only a minor role in therapy for 
psoriasis. This study reveals that treatment with histamine 
2 receptor agonists, and blockade of the histamine 4 recep-
tor ameliorates inflammation in a mouse model of psoriasis 
and diminishes psoriasis-associated itch. Histamine 2 re-
ceptor agonists and histamine 4 receptor antagonists might 
thus be new targets to treat psoriasis.
Psoriasis is a chronic inflammatory skin disorder char­
acterized by hyperproliferative keratinocytes and im­
mune cell infiltration into the skin, often accompanied 
by itch. Histamine, acting via histamine 1–4 recep­
tors, is known to modulate immune responses in the 
skin and to induce itch. The aim of this study was to 
test the role of histamine 2 receptors and histamine 
4 receptors in the imiquimod­induced psoriasis­like 
skin inflammation model. BALB/c mice were treated 
intraperitoneally with amthamine (histamine 2 re­
ceptor agonist), JNJ­39758979 (histamine 4 receptor 
antagonist), a combination of both, or vehicle twice 
daily in a preventive manner. Imiquimod was applied 
once daily onto the back skin for 10 consecutive days. 
Stimulation of histamine 2 receptors and blockade of 
histamine 4 receptors ameliorated imiquimod­induced 
skin inflammation. The combination of amthamine and 
JNJ­39758979 reduced skin inflammation even more, 
diminished epidermal hyperproliferation, and inhibited 
spontaneous scratching behav iour. A combination of 
histamine 2 receptor agonist and histamine 4 receptor 
antagonists could represent a new strategy for the tre­
atment of psoriasis.
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Psoriasis is a chronic autoimmune disease characte-rized by a hyperproliferative epidermis consisting 
of premature keratinocytes, incomplete cornification 
and an elevated immune cell infiltration (1). Psoriasis 
is mediated by complex interactions between immune 
cells, especially T cells, antigen presenting cells, and 
keratinocytes. Histamine might play a pathogenetic role 
in psoriasis, since histamine increases the proliferation 
of keratinocytes, and elevated histamine levels can 
be found in psoriatic skin (2–4). Histamine acts via 4 
G-protein-coupled receptors, histamine 1–4 receptors 
(H1–4R). Whilst activation of H1R and H4R, in general, 
elicit a pro-inflammatory immune response, activation 
of H2R is associated with regulatory immune responses. 
In a mouse model of atopic dermatitis, dual treatment 
with an H4R and H1R antagonist diminished the inflam-
matory response in the skin (5). It has been shown that 
H4R, but not H1R or H2R, modulates the proliferation 
of keratinocytes (4). Furthermore, plasmacytoid dendri-
tic cells (pDC) isolated from skin and blood of patients 
with psoriasis highly express H4R. H4R was shown to 
influence cytokine production and migration of pDC 
(6). This subpopulation of dendritic cells can produce 
massive amounts of pro-inflammatory cytokines and are 
absent in healthy skin (7). According to these findings, 
H4R antagonists might provide a new strategy to treat 
psoriasis. However, a recent study by Kim et al. (8) 
showed that the dual H2R/H4R agonist 4-methylhistami-
ne reduced imiquimod (IMQ)-induced psoriasis-like skin 
inflammation in mice, arguing against this hypothesis. 
Thus, the aim of this study was to test the role of H2R 
and H4R in a mouse model of psoriasis, the IMQ model. 
MATERIALS AND METHODS 
Mice
Female BALB/c mice (BALB/cAnNCrl, 7 ± 1 weeks-old, body 
weight 20 ± 1 g) were obtained from Charles River (Sulzfeld, Ger-
many). H4R knockout (H4R–/–) mice were generated by Lexicon 
Genetics (Woodlands Park, TX, USA) and provided by Janssen 
Research & Development, LLC, La Jolla, CA, USA and backcros-
sed for more than 10 generations onto the BALB/c strain. The 
animal experiment has been approved by the Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit, Ol-
denburg, Germany (AZ. G33.12-42502-04-15/1899). All animals 
were healthy and were housed in groups of 7 mice per Eurostan-
dard type cages (macrolone, 825 cm² of space), at 22°C with a 
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12-h light/dark cycle and wood shavings as bedding material. A 
mouse house and paper tissues as nesting material were used as 
environmental enrichment. Water and a standard diet (Altromin, 
Lage, Germany) were available ad libitum. 
Imiquimod-induced skin inflammation
Mice were acclimatized to their environment for 2 weeks before the 
experiments. The animals were randomly allocated into treatment 
and vehicle group (n = 7 per group). In the experiment with H4R–/– 
mice, n = 6 H4R–/– mice and n = 6 wild-type mice were used. Sample 
size calculation was performed by power analysis using G*power 
3.1.9.2. for Windows (alpha value 0.5, power 80%, Cohen’s d ef-
fect size 0.8). A co-worker blinded to the experimental protocol 
randomized animals into these groups. Mice were treated with 
Aldara™ (MEDA Pharma GmbH & Co. KG, Bad Homburg, Ger-
many) cream (containing 5% IMQ) to induce psoriasis-like skin 
inflammation. This is referred as “IMQ” throughout the current 
paper. Mice were killed 24 h after the last application of IMQ or 
soft cream. Mice were killed by inhalation of isoflurane, followed 
by cardiac puncture for blood collection. Animal experiments 
were performed in accordance with the recommendations in the 
ARRIVE guidelines (https://arriveguidelines.org/). 
Treatment groups
Five independent experiments were performed. Experiment 1: 
soft cream vs IMQ (this experiment is referred as the “control” 
throughout this paper). Soft cream was used as the vehicle cream 
for the IMQ-containing Aldara™ cream. Experiment 2: Treatment 
with H2R agonist amthamine administered intraperitoneally (i.p.) 
and IMQ topically (H2R + IMQ) vs treatment with vehicle (aqua 
ad injectionem) i.p. and IMQ topically (vehicle + IMQ). Experi-
ment 3: Treatment with H4R antagonist JNJ-39758979 i.p. and 
IMQ topically (H4R + IMQ) vs treatment with vehicle (aqua ad 
injectionem) i.p. and IMQ topically (vehicle + IMQ). Experiment 
4: Treatment with amthamine plus JNJ-39758979 i.p. and IMQ 
topically (H2R + H4R+ IMQ) vs treatment with vehicle (aqua ad 
injectionem) i.p. and IMQ topically (vehicle + IMQ). Experiment 
5: Wild-type mice treated with IMQ topically vs H4R–/– mice 
treated with IMQ topically.
Drug administration
IMQ or soft cream were applied once daily onto the shaved back 
skin (30 mg). The IMQ model was modified to 30 mg on back skin, 
since 50 mg induced quite severe inflammation that could be redu-
ced only moderately, even by a strong topical corticosteroid, such 
as diflorasone-diacetate. H2R agonist amthamine, H4R antagonist 
JNJ-39758979, a combination of amthamine+JNJ-39758979 or 
vehicle (aqua ad injectionem) i.p. twice daily for 17 days. Drug 
administration commenced one week prior to application of IMQ 
cream. All substances were given at a dosage of 20 mg/kg body 
weight twice daily. 
Assessment of severity of dermatitis 
Severity of inflammation of the back skin was evaluated using 
a modified Psoriasis Area and Severity Index (PASI) by blinded 
investigators. Mice were assessed individually regarding erythema, 
scaling and thickening, on a scale from 0 (no symptoms) to 4 
(marked symptoms). These 3 individual assessments were summed 
in a cumulative score from 0 to 12 (total skin score).
Analyses of spontaneous scratching behaviour 
Scratching behaviour was determined from day 3 to 10 before 
topical application of IMQ (i.e. 23 h after the last topical applica-
tion). Mice were recorded on video for 30 min and scratching bouts 
on the back and the treated ear with the hind paws were analysed.
Histological analysis of the skin
Lesional skin sites of the back were separated, fixed and paraffin 
sections stained with haematoxylin and eosin (H&E). Sections 
were analysed under light microscopy by a blinded observer. 
Epidermal thickness of 10 randomly selected areas was assessed 
using Axiovision 4.8 software (Carl Zeiss, Oberkochen, Germany). 
Total inflammatory cell influx was determined semiquantitatively 
by a score system ranging from “–” (none) to “’++++”4 (very 
high cell influx).
Cytokine determination in the skin
Skin was homogenized at first and the total protein concentration 
of each skin specimen was determined to normalize the protein 
content between multiple samples. In brief, skin samples were 
homogenized under liquid nitrogen, transferred to RPMI 1640 
medium and 1 mmol/l Pefabloc, and mixed intensively. After 
centrifugation the supernatants were collected and the protein 
content was determined with a protein assay. Interleukins (IL)-
17A, IL-23, IL-33 and tumour necrosis factor alpha (TNF-α) were 
measured by enzyme-linked immunoassay (ELISA) according to 
the manufacturer’s instructions. 
Single cell preparation of lymph nodes 
The skin-draining lymph nodes (Lnn. axilliares) were isolated 
and single cell suspensions were counted in a Neubauer chamber. 
Data analysis
Five different experiments were performed. Statistical signifi-
cances between 2 groups were assessed by Mann–Whitney U 
test using GraphPad Prism version 7.00 for Windows (Graph-
Pad Software, La Jolla, CA, USA). p-values < 0.05 were 
considered statistically significant. The PASI score and the 
scratching behaviour were analysed with 2-way analysis of 
variance (ANOVA) followed by Sidak’s multiple comparisons 
test. Data given in the text and in the graphs are presented as 
mean ± standard deviation of the mean (SD). All experiments 
were conducted/analysed in a blinded manner (all researchers 
were unaware of which treatment each subject has received 
until after the experiment was over). 
Materials 
IMQ (Aldara™ 5% Crème) was obtained from Meda Pharm 
GmbH & Co. KG (Bad Homburg v.d. Höhe, Germany). As vehicle 
cream a soft cream was used containing (w/w) of 32.5% paraf-
fin, 22.7% white petrolatum, 3.2% glycerol monostearate 40–50, 
2.1%, sorbitanmonostearate, 4.4% polyoxyl ethylene glycol(30)-
stearat, 0.1% citric acid monohydrate, 21% H2O, 5% urea, 8.5% 
glycerin 85% and 0.5% phenoxetol. The vehicle cream was 
made by a local pharmacy (Apotheke Großer Hillen, Hannover, 
Germany). Amthamine dihydrobromide was obtained from 
Tocris Bioscience (Bristol, UK). JNJ-39758979 was provided by 
Janssen Research & Development (La Jolla, CA, USA). Bovine 
serum albumin was purchased from Sigma-Aldrich (Darmstadt, 
Germany). RPMI 1640 medium was purchased from Biochrom 
GmbH (Berlin, Germany). Pefabloc was obtained from Roche 
Diagnostics (Basel, Switzerland). The protein assay was obtained 
from Bio-Rad Laboratories GmbH (München, Germany). All 
ELISAs (IL-17A, IL-23, IL-33 and f-α) were obtained from R&D 
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RESULTS
Blockade of histamine 4 receptors and stimulation of 
histamine 2 receptors reduced imiquimod-induced skin 
inflammation
Topical application of IMQ induced local inflammation 
with erythema, thickening and scaling of the skin (Fig. 1 
and Fig. S11). Clinical parameters increased continuously 
over the first 6 days of application and reached a plateau 
or decreased slightly by day 7 (Fig. 1). Mice treated with 
soft cream (vehicle cream) did not develop any visible 
signs of skin inflammation, and were scored with 0 at 
any day and any parameter (Fig. 1 and Fig. S11). The 
total skin score was slightly reduced in mice treated 
systemically with the H2R agonist amthamine, but only 
significantly on days 3 and 4. Starting at day 6 of IMQ 
treatment, the H4R antagonist JNJ-39758979 reduced 
the total skin score (significantly only on day 10) (Fig. 
1A). H4R–/– mice had a lower total skin score starting 
from day 5 compared with wild-type mice (Fig. 1). The 
combination of amthamine and JNJ-39758979 led to the 
strongest reduction in total skin score (Fig. 1). On day 
3 after starting the experiment, one of the mice treated 
with amthamine died immediately after intraperitoneal 
injection. Necropsy showed that a large blood vessel was 
inadvertently damaged by the needle.
Combination of an H2R agonist and an H4R antagonist 
completely abolished scratching behaviour
Spontaneous scratching behaviour was analysed daily 
(starting at day 3) 23 h after the last application of 
IMQ. Mice treated with IMQ showed more scratching 
bouts compared with mice treated with soft cream (Fig. 
2A). In amthamine + IMQ-treated mice, the scratching 
response was not significantly altered compared with 
vehicle + IMQ-treated mice (Fig. 2B). In mice treated 
with JNJ-39758979 + IMQ the scratching response was 
reduced only slightly, if at all (Fig. 2C). The combina-
tion of amthamine and JNJ-39758979 almost completely 
abolished the IMQ-induced scratching behaviour (Fig. 
2D). Comparable to the lack of efficacy of the H4R 
antagonist alone, also in H4R–/– mice, no difference in 
the scratching behaviour was detected compared with 
wild-type mice (Fig. 2E). 
Epidermal thickening was lower in mice treated with 
H2R agonist or H4R antagonist 
Amthamine and JNJ-39758979-attenuated IMQ-induced 
epidermal thickening. IMQ strongly increased the epi-
dermal thickness, from approximately 20 ± 3 µm in mice 
treated with soft cream (control) to 60 ± 10 µm in mice 
treated with IMQ (Fig. 3; control). In mice treated with 
amthamine, JNJ-39758979 or the combination of both, 
the thickness of the epidermis was significantly lower 
than in the corresponding vehicle groups (Fig. 3). The 
Fig. 1. Histamine 2 receptor (H2R) stimulation and histamine 4 receptor (H4R) blockade reduced imiquimod (IMQ)­induced skin 
inflammation. (A) Severity of inflammation of the back skin was evaluated using a modified Psoriasis Area and Severity Index (PASI). Scores (0–4) of the 
3 parameters (scaling, thickening, erythema) were summed in a cumulative score from 0 to 12 (total skin score). In mice treated with the vehicle cream 
(soft cream) instead of IMQ, no signs of skin inflammation were visible. Total skin score was slightly reduced in mice treated with amthamine administered 
intraperitoneally (i.p.) (H2R) or with JNJ-39758979 i.p. (H4R) compared with the corresponding vehicle groups. Total skin score was reduced in H4R–/– 
mice compared with wild-type mice. In mice treated with the combination of amthamine and JNJ-39758979 (H2R+H4R) the total skin score was clearly 
reduced; n = 6 BALB/c mice treated with amthamine and n = 7 BALB/c mice all other treatment groups; n = 6 wild-type and n = 6 H4R–/– mice; *p < 0.05, 
**p < 0.01, ***p < 0.001. Two-way analysis of variance (ANOVA) followed by Sidak’s multiple comparisons test. Data are presented as mean ± standard 
deviation (SD). All drugs were given at a dosage of 20 mg/kg i.p. twice daily and were compared with treatment with vehicle (aqua ad injectionem, 
twice daily i.p.). (B) Clinical signs on day 10 of one representative mouse per group. Mice show erythema, scaling and thickening of the back skin. Mice 
treated with vehicle cream (soft cream) instead of IMQ did not develop signs of skin inflammation. Clinical signs were less severe in mice treated with 
the H2R agonist amthamine (H2R), with the H4R antagonist JNJ-39758979 (H4R). H4R–/– mice showed less severe scaling than wild-type mice on day 
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thickness of the epidermis was lower in H4R–/– mice, but 
only by trend (Fig. 3).
Amthamine and JNJ-39758979 reduced dermal lympho-
cytic cell infiltrates
In the skin of mice treated topically with soft cream, 
no lymphocytic infiltration was visible, whereas mice 
treated with IMQ showed a marked dermal infiltration of 
lymphocytic cells (Fig. 4A, B). In the skin of mice treated 
with the H2R agonist amthamine plus IMQ, lymphocytes 
persisted in the dermal layer, but the infiltration appeared 
to be less severe than in mice treated with vehicle plus 
IMQ (Fig. 4C, E). In the skin of mice treated with the 
combination of amthamine and JNJ-39758979 plus IMQ, 
lymphocytic infiltration of the dermis could only rarely 
be detected (Fig. 4H), whereas in the corresponding 
vehicle group a marked lymphocytic infiltration was 
again visible (Fig. 4G). In H4R–/– mice, lymphocytes 
persisted in the dermal layer, but infiltration appeared to 
be less severe than in wild-type mice (Fig. 4I, J).
H4R blockade reduces the number of lymph node cells 
IMQ significantly increased the number of skin-draining 
lymph node cells compared with mice treated with soft 
cream (Fig. 5). The IMQ-induced increase was signifi-
cantly lower in mice treated with H4R antagonist, but 
not in mice treated with H2R agonist compared with 
the corresponding vehicle groups (Fig. 5). Combination 
of JNJ-39758979 with H2R agonist clearly reduced the 
number of skin-draining lymph node cells compared 
with mice treated with vehicle (Fig. 5). In H4R–/– mice, 
the total number of skin-draining lymph node cells was 
significantly lower than in wild-type mice.
H4R blockade and H2R stimulation alone reduced pro-
inflammatory cytokines in lesional skin
Significantly increased levels of Th17 cytokines IL-17A 
and IL-23 and of the Th1 cytokines (TNF-α and IL-33) 
were detected in the IMQ-treated skin at protein level 
compared with mice treated with soft cream (data not 
shown). The level of TNF-α was not significantly influ-
enced by any treatment, and not reduced in H4R–/– mice 
compared with the corresponding vehicle groups or 
wild-type mice, respectively (Fig. S2A1). The increase 
in IL-33 and IL-23 was diminished in amthamine and 
JNJ-39758979-treated mice, but not in mice treated with 
the combination of both drugs (Fig. S2B, D1). The content 
of IL-17A in the skin was only significantly lowered by 
Fig. 2. Combined treatment with amthamine and JNJ­39758979 administered intraperitoneally (i.p.) 
inhibited imiquimod (IMQ)­induced scratching behaviour. (A) Mice treated with IMQ showed an increased 
scratching behaviour compared with mice treated with soft cream. (B) Amthamine i.p. (H2R+IMQ) did not reduce 
the IMQ-induced scratching behaviour. (C) In mice treated with JNJ-39758979 i.p. + IMQ topically (H4R+IMQ), 
the scratching response was lower than in mice treated with vehicle i.p. + IMQ topically, but only on days 3 and 
6, the scratching behaviour was significantly reduced. (D) The combination of amthamine and JNJ-39758979 i.p. 
(H2R+H4R+IMQ) almost completely inhibited IMQ-induced scratching behaviour compared with the corresponding 
vehicle group. (E) IMQ-induced scratching response did not differ between wild-type and H4R–/– mice. **p < 0.01, 
***p < 0.001 2-way analysis of variance (ANOVA) followed by Sidak’s multiple comparisons test. n = 6 BALB/c 
mice treated with amthamine and n = 7 BALB/c mice all other treatment groups; n = 6 wild-type and n = 6 H4R–/– 
mice. Data are presented as mean ± standard deviation of the mean (SD). All drugs were given in a dosage of 
20 mg/kg i.p. twice daily and were compared with treatment with vehicle (aqua ad injectionem, twice daily i.p.).
Fig. 3. Amthamine and JNJ­39758979 attenuated imiquimod (IMQ)­
induced epidermal thickening. IMQ strongly increased the epidermal 
thickness from approximately 20 ± 3 µm in mice treated with soft cream 
(control, far left) to 60 ± 10 µm in mice treated with IMQ. In mice treated 
with amthamine administered intraperitoneally (i.p.) and IMQ topically 
(histamine 2 receptor (H2R)+IMQ), the thickness of the epidermis was 
significantly lower than in mice treated with vehicle i.p. + IMQ topically 
(vehicle + IMQ). Also in mice treated with JNJ-39758979 i.p. + IMQ topically 
(histamine 4 receptor (H4R) + IMQ) or a combination of amthamine and 
JNJ-39758979 i.p. + IMQ topically (H2R+H4R+IMQ), the epidermis was 
significantly thinner than the epidermis of the corresponding vehicle 
groups (vehicle + IMQ). The epidermal thickness of wild-type (referred 
as “vehicle + IMQ”) and H4R–/– mice (referred as “treatment + IMQ”) was 
not significantly different. *p < 0.05 Mann–Whitney test. n = 6 BALB/c mice 
treated with amthamine and n = 7 BALB/c mice all other treatment groups; 
n = 6 wild-type and n = 6 H4R–/– mice. All drugs were given in a dosage of 
20 mg/kg i.p. twice daily and were compared with treatment with vehicle 
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H2R agonist (Fig. S2C1). In H4R–/– mice, a significantly 
lower amount of IL-17A and IL-23 was measured com-
pared with wild-type mice, whereas IL-33 did not differ 
between groups (Fig. S2B–D1). 
DISCUSSION 
Topical application of IMQ cream induces an inflam-
matory response in the skin that mimics psoriasis, with 
similar immunological pathways and cell types involved 
(9, 10). Since its introduction in 2009 by van der Fits et 
al. (10), it has become a widely used standard mouse 
model to mimic psoriasis and its associated itch. 
Clinical cutaneous manifestations of psoriasis are di-
verse, but a hallmark of psoriasis is epidermal thickening 
and scaling (10). The H4R antagonist JNJ-39758979, as 
well as the H2R agonist amthamine, clearly reduced the 
scaling response and thickening. In a previous study, we 
showed that histamine induces proliferation of keratino-
cytes via activation of H4R (4). H2R ligands, in contrast, 
did not influence the proliferation of keratinocytes (4). 
In this study, however, the H2R agonist reduced IMQ-
induced scaling and epidermal thickening. In line with 
this, topical treatment with an H2R antagonist stimulated 
epidermal proliferation after barrier disruption in mice 
(12). Thus, H2R most likely does not affect keratinocytes 
directly, but might influence proliferation-modulatory 
extracellular signals, such as the cytokine network in 
the local microenvironment. 
Sakai et al. (13) reported that IMQ induces increased 
scratching behaviour in mice compared with vehicle 
cream, indicating that the IMQ-induced psoriasis model 
Fig. 4. Imiquimod (IMQ)­induced dermal lymphocytic cell infiltrates. 
Representative histological pictures of lymphocytic cell infiltrates (asterisks) 
in the dermis. The treatment of mice using a combination of JNJ-39758979 
and amthamine reduced lymphocytic cell infiltrates (asterisks) in the dermis. 
Skin of mice was treated topically with (A) soft cream or (B–J) IMQ for 10 
consecutive days. (A) Skin of mice treated topically with soft cream. No 
lymphocytic infiltration (score (–)) was visible. (B) Skin of mice treated with 
IMQ topically. Lymphocytic infiltration (++++) is visible. (C, E, G) Skin of 
mice treated with vehicle administered intraperitoneally (i.p.) + IMQ topically. 
Lymphocytes (++++) persisted in the dermal layer (asterisks). (D) Skin of 
a mouse treated with amthamine i.p. + IMQ topically. Lymphocytes (+++) 
persisted in the dermal layer (asterisks), but infiltration appeared to be less 
severe than in mice treated with vehicle i.p. + IMQ topically (C). (F) Skin of 
a mouse treated with JNJ-39758979 i.p. + IMQ topically. Lymphocytes (+++) 
persisted in the dermal layer (asterisks), but infiltration appeared to be less 
severe than in mice treated with vehicle i.p. + IMQ topically (E). (H) Skin 
of a mouse treated with amthamine + JNJ-39758979 i.p. + IMQ topically. 
Lymphocytic infiltration (+) of the dermis could only rarely be detected. All 
drugs were given in a dosage of 20 mg/kg i.p. twice daily and were compared 
with treatment with vehicle (aqua ad injectionem, twice daily i.p.). (I) Skin of 
a wild-type mouse treated with IMQ topically. Lymphocytes (++++) persisted 
in the dermal layer (asterisks), infiltration appeared to be more severe than 
in H4R–/– mice (+++, J). Bars represent 50 µm.
Fig. 5. Histamine 2 receptor (H2R) stimulation and histamine 4 
receptor (H4R) blockade diminished imiquimod (IMQ)­induced 
increase in the cell number of skin­draining lymph nodes. IMQ greatly 
increased the total number of cells in the axillary lymph nodes. This increase 
was significantly reduced by amthamine (H2R), JNJ-39758979 (H4R) or 
the combination of both (H2R + H4R) compared with the corresponding 
vehicle (vehicle + IMQ) groups. Also, in H4R–/– mice, a significantly lower 
number of draining lymph node cells were detected compared with wild-
type mice (named “vehicle” in the graph). *p < 0.05 Mann–Whitney test. 
n= 6 BALB/c mice treated with amthamine and n= 7 BALB/c mice all other 
treatment groups; n= 6 wild-type and n= 6 H4R–/– mice. All drugs were 
given in a dosage of 20 mg/kg administered intraperitoneally (i.p.) twice 
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seems to be useful for the investigation of psoriatic itch. 
Interestingly, the combination of amthamine and JNJ-
39758979 completely abolished spontaneous scratching 
behaviour in the IMQ model in the current study. Several 
studies in rodents and humans emphasize the role of 
H4R in histamine- and allergen-induced itch (14–18). 
Involvement of H2R in itch transmission, in contrast, is 
generally believed to be only marginal if at all (19). H2R 
agonists do not induce itch in humans or mice, and H2R 
antagonists do not inhibit histamine- or allergen-induced 
itch (15, 20, 21). However, in this study, the combina-
tion of an H2R agonist and an H4R antagonist almost 
completely abolished scratching behaviour, whereas the 
H4R antagonist alone did not. Whether itch response was 
because of the reduced skin score, or vice versa, the cause 
of reduced clinical score is not clear. In patients with 
psoriasis, there is not necessarily a correlation between 
the severity of the disease and the intensity of pruritus 
(22). The role of histamine in the pathogenesis of itch in 
psoriasis is unclear. Two studies showed that histamine 
levels in psoriatic skin were higher than those in healthy 
skin (2, 3). A more recent study, in contrast, found similar 
histamine levels in skin from healthy subjects and in 
psoriatic skin (23). Sakai et al. (13) reported that the 
expression level of histamine in IMQ-treated murine 
skin peaked on day 2 of IMQ treatment and returned to 
the basal level on day 3–7. Interestingly, JNJ-39758979 
significantly reduced the scratching behaviour only on 
days 3 and 6 of IMQ treatment, which might be related 
to the histamine level in the skin. Both, H2R and H4R 
are expressed on murine dorsal root ganglia (DRG) 
and, for H4R at least, it was shown that stimulation of 
the receptor leads to Ca2+ influx in DRG (14). Thus, the 
anti-pruritic action of H4R antagonist might be a direct 
effect on sensory neurones. 
Patients with psoriasis, as well as IMQ-treated mice, 
show increased production of the pro-inflammatory 
cytokines TNF-α and IL-33, as well as Th17 cytokines 
IL-17A and IL-23 (9-11, 24, 25), as confirmed in the cur-
rent study. IL-23 induces IMQ- and psoriasis-associated 
epidermal hyperplasia and indirectly stimulates kerati-
nocyte proliferation (24, 25). Increased levels of IL-17 
mRNA and T cells producing IL-17 are found in psoriatic 
tissues (26). Mommert et al. (27) showed that activa-
tion of H4R stimulates Th17 cells to release enhanced 
amounts of IL-17, indicating that H4R leads to an exacer-
bation of inflammatory skin diseases, such as psoriasis. 
Inhibition of H4R and stimulation of H2R, how ever, 
decreased the IL-33 level in the skin. IL-33 levels are 
increased in skin lesions of patients with psoriasis, and 
it has been shown that psoriatic keratinocytes secrete 
this pro-inflammatory cytokine (28). The interaction 
of IL-33 with neutrophils and mast cells leads to a skin 
inflammation in mice that is similar to psoriatic plaques 
in humans (29). However, skin inflammation in the IMQ 
model did not differ between wild-type and IL-33–/– mice 
(30). In line with this, in the current study skin lesions 
were ameliorated in mice treated with a combination of 
amthamine and JNJ-39758979, even though the content 
of IL-33 was not decreased in the skin. Thus, reduced 
levels of the cytokines tested is probably not responsible 
for the anti-inflammatory effect seen by the treatment 
with amthamine plus JNJ-39758979. 
Cell numbers of skin-draining lymph nodes were 
significantly reduced by amthamine and JNJ-39758979, 
underlining the reduction in the inflammatory response 
with these drugs. It was shown that topical application 
of IMQ yields systemic effects due to unintended oral 
uptake (31). JNJ-39758979 and the combination of 
amthamine and JNJ-39758979 could lower this reaction. 
At sites of inflammation, Th1 and Th2 cells play im-
portant roles. It has been shown that both Th1- and Th2-
type responses are negatively regulated by H2R through 
the activation of different biochemical intracellular sig-
nals. Mice lacking H2R showed an upregulation of both 
Th1 and Th2 cytokines, indicating an anti-inflammatory 
role of H2R (32). In human blood cells stimulation via 
H2R leads to an up-regulation of IL-10 and downregula-
tion of IL-12. Antigen-presenting cells that are activated 
via H2R show a suppression of antigen presentation and 
lead to the formation of IL-10-producing T cells (revie-
wed in (33)). Also, pro-inflammatory responses to Toll 
like receptor (TLR) agonists are suppressed by histamine 
through H2R (34). This is interesting, as IMQ acts (at 
least partly) via activation of TLR7/8. Moreover, patients 
with chronic inflammation of the gut (Crohn’s disease) 
display dysregulated expression of histamine receptors, 
with diminished anti-inflammatory effects associated 
with H2R signalling (35). In summary, activation of 
H2R displays mainly anti-inflammatory properties that 
might also be beneficial in the context of psoriasis. 
System ically, H2R agonist might not be well tolerated 
in humans, due to gastrointestinal or cardiac side-effects; 
however, topical application might be an option for 
psoriatic patients. H2R agonists have not been tested in 
psoriatic patients to date, but H2R antagonists have. They 
are not effective in the treatment of psoriasis, and some 
studies even report a worsening of the disease within the 
first month after treatment with H2R antagonists (36–39). 
Kristensen et al. (36) reported that the worsening seen 
after the first month of treatment with ranitidine was 
principally manifested as itching and increased redness. 
Interestingly, in the current study, amthamine signifi-
cantly reduced the itch response and erythema within 
the first days of treatment, but not at a later time-point. 
An H4R antagonist phase 2 clinical trial has been com-
pleted in patients with moderate-to-severe plaque-type 
psoriasis (40). The H4R antagonist was able to reduce 
the PASI score by a greater extent than placebo, but it 
did not meet the predefined success criterion (40). Thus, 
as in the mouse model, and in humans, blockade of H4R 
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The results of the current study are contrary to those 
of Kim et al. (8), who showed that the H4R agonist 
4-methyl histamine alleviated psoriatic symptoms in a 
dose-dependent fashion in the IMQ model. However, 
despite the relatively low affinity of 4-methylhistamine 
at H2R, it shows considerable in vivo H2R agonistic acti-
vities at dosages > 3 mg/kg i.v. in rodents (41). Reduction 
in skin lesions and epidermal thickening were seen at 
dosages of at least 20 mg/kg/day for 10 consecutive days, 
in a study by Kim et al. (8). Thus, the anti-inflammatory 
properties of 4-methylhistamine might be due to agonis-
tic activity at H2R rather than agonistic activity at H4R. 
In conclusion, this study found that combined treat-
ment with an H2R agonist and H4R antagonist amelio-
rated skin inflammation and pruritus in a mouse model 
of psoriasis. 
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